Equity Profile

INDV

Indivior Pharmaceuticals, Inc.

Health CarePharmaceuticals$4.5B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and delivering innovative treatments for addiction and other mental health conditions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and investor returns, and this quarter's estimate reflects strong performance expectations.

$1.12

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$329M

Wall Street expectations, options signals, track record, and call prep available with Pro.

INDV Q2-2026 Earnings Preview

Context

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and delivering innovative treatments for addiction and other mental health conditions. With a market cap of $5 billion, it plays a crucial role in addressing the growing need for effective therapies in the pharmaceutical industry.

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+68.40%

Avg Stock Reaction

+9.86%

Last Quarter Recap

In Q1-2026, Indivior reported an EPS of $0.96, significantly exceeding the estimate of $0.64, which led to a stock increase of 7.70% the following day. The company continues to show strong growth momentum.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Indivior to report solid earnings this quarter, with estimates indicating continued growth in both EPS and revenue. The company has consistently beaten earnings expectations in recent quarters.

Bull Case

If Indivior continues its trend of exceeding earnings estimates, it could signal strong demand for its products and lead to further stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth trajectory and negatively impact the stock.

Key Metrics to Watch

EPS

$1.12

Earnings per share is a key indicator of profitability and investor returns, and this quarter's estimate reflects strong performance expectations.

Revenue

$329M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $1.12?

Given the company's history of beating estimates, a strong EPS could reinforce investor confidence and drive the stock higher.

What guidance will management provide regarding future revenue growth?

Investors will closely watch for any indications of sustained growth or potential challenges in the market.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the strength of Indivior's product demand, particularly in light of recent positive earnings surprises.

Supporting Evidence

Indivior has consistently beaten EPS estimates, indicating stronger-than-expected performance.

The options market is pricing a significant move, suggesting that traders anticipate volatility and potential upside.

Key Risk

If the company reports an EPS significantly above $1.12, it could challenge the current consensus and lead to a re-evaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the potential for continued strong performance against the risks of missing expectations.

Bull Confirmed If

An EPS of $1.15 or higher would confirm the bullish sentiment and indicate strong operational performance.

Bear Confirmed If

An EPS below $1.09 would raise concerns about the company's growth prospects and could lead to a sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±20.61%

Historical Avg

±9.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.

Options are pricing ±20.6% while INDV has averaged ±9.9% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

36.0%

Calls (1K)P/C Ratio: 0.24Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Indivior beats expectations, history suggests the stock could rise by around 9.86%, confirming the bullish outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors digest management's commentary.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around 9.86% following an earnings miss.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management and operational efficiency.
4Guidance on revenue expectations for the next quarter.
5Responses to any regulatory changes affecting the business.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and delivering innovative treatments for addiction and other mental health conditions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and investor returns, and this quarter's estimate reflects strong performance expectations.

$1.12

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$329M

Wall Street expectations, options signals, track record, and call prep available with Pro.

INDV Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+68.40%

Avg Stock Reaction

+9.86%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Indivior continues its trend of exceeding earnings estimates, it could signal strong demand for its products and lead to further stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth trajectory and negatively impact the stock.

Key Metrics to Watch

EPS

$1.12

Earnings per share is a key indicator of profitability and investor returns, and this quarter's estimate reflects strong performance expectations.

Revenue

$329M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $1.12?

Given the company's history of beating estimates, a strong EPS could reinforce investor confidence and drive the stock higher.

What guidance will management provide regarding future revenue growth?

Investors will closely watch for any indications of sustained growth or potential challenges in the market.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the strength of Indivior's product demand, particularly in light of recent positive earnings surprises.

Supporting Evidence

Indivior has consistently beaten EPS estimates, indicating stronger-than-expected performance.

The options market is pricing a significant move, suggesting that traders anticipate volatility and potential upside.

Key Risk

If the company reports an EPS significantly above $1.12, it could challenge the current consensus and lead to a re-evaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the potential for continued strong performance against the risks of missing expectations.

Bull Confirmed If

An EPS of $1.15 or higher would confirm the bullish sentiment and indicate strong operational performance.

Bear Confirmed If

An EPS below $1.09 would raise concerns about the company's growth prospects and could lead to a sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±20.61%

Historical Avg

±9.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.

Options are pricing ±20.6% while INDV has averaged ±9.9% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

36.0%

Calls (1K)P/C Ratio: 0.24Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Indivior beats expectations, history suggests the stock could rise by around 9.86%, confirming the bullish outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors digest management's commentary.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around 9.86% following an earnings miss.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management and operational efficiency.
4Guidance on revenue expectations for the next quarter.
5Responses to any regulatory changes affecting the business.